Close Menu

cancer of unknown primary

In a document filed with the SEC, the Israeli firm disclosed that problems with a reagent used for testing could have affected results for about 100 miRview mets tests performed in the company's CLIA laboratory between August and October.

Pharmacogenomics Reporter took stock of industry expectations ahead of FDA's upcoming meeting to discuss the agency's strategy for regulating laboratory-developed tests.

Spain's Ferrer InCode will market BioTheranostics molecular diagnostic cancer test in Spain, Portugal, Greece, and Venezuela.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.